Omnicell stock: buy or sell?
September 20th, 2019
Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide.
Should I buy Omnicell stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to choose your own trading plan that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Omnicell stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Omnicell stock a buy?
Financial institutions and banks publish stock ratings everyday.At Stocks2.com, we gathered 3 ratings published for OMCL stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-3-7||Dougherty & Co||n/a||Buy|
|2019-2-8||Piper Jaffray Companies||n/a||Neutral|
Omnicell stock analysis
Omnicell appreciated a beatiful 1.11% and closed at $74.41.
Shares of Omnicell appreciated a beatiful 1.11% and closed at $74.41. Since price and SMA200d lines crossed down on August, OMCL fell $-0.80 per share (-1.06%). On June, OMCL hit new all time highs, pushing higher previous ATH of $91.22 recorded on June. New ATHs are usual entry points for many trading setups as there aren't higher resistences.
Shares of Omnicell appreciated a slightly fine 0.94% this week. This week was the 5th green week in a row. Late July OMCL plummed a frightening -5.55% in just one week.
In a weekly time frame, Omnicell stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, OMCL might consolidate in a flat-base, waiting to break out over or down under . Not so far away is the last all-time high Omnicell marked by mid June, but since then it dropped a 19.63%. Since price and 40-weeks moving average lines crossed down early July, OMCL fell $-11.87 per share (-13.76%). Trading stocks that are under the 40-weeks (that is, 200-days) moving average mark is not recommended by many experts, as it indicates that the stock has not enough institutional support.
Omnicell stock price history
Omnicell IPO was on August 9th, 2001 at $8.71 per share1. Since then, OMCL stock grew a 754.30%, with a yearly average of 41.90%. If you had invested $1,000 in Omnicell stock in 2001, it would worth $7,543.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Omnicell stock historical price chart
OMCL stock reached all-time highs on June with a price of $92.59.
Omnicell stock price target is $81.70Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. We found 3 price forecasts for Omnicell stock released in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-3-7||Dougherty & Co||Raises Target||$78.00||$90.00||15.4%|
|2019-2-8||Piper Jaffray Companies||Reiterates||n/a||$70.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter presenting its last earnings report on April, Omnicell . Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual sales report draw a superb growth of 10.47% to $787.31 million dollars. On the other hand, its income margin (compared to revenues) stayed stable to 4.79%, that is $37.73 million. Omnicell presents anual results in December, and to evaluate its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Omnicell TTM sales up to March 2019 were $807.21 and income $38.29 million dollars. When comparing this TTM figures with the last reported annuality, we can review Omnicell business evolution since December 2018: Annual revenues up to March, compared to lastest yearly report, gained a slightly good 2.53%. Nevertheless, profit margin (net income/revenues) stayed constant at 4.79%.
|2013||$381 M||-||$24 M6.3%||-|
|2014||$441 M||15.85%||$31 M6.9%||27.26%|
|2015||$485 M||9.90%||$31 M6.3%||0.79%|
|2016||$693 M||42.94%||$0.60 M0.1%||-98.04%|
|2017||$713 M||2.90%||$31 M4.3%||4,961.03%|
|2018||$787 M||10.47%||$38 M4.8%||23.63%|
|TTM||$807 M||2.53%||$38 M4.7%||1.49%|
Quarterly financial resultsOmnicell reported $202.52 M in sales for 2019-Q1, a -4.36% decline compared to previous quarter. Reported quarter earnings marked $3.28 million with a profit margin of 1.62%. Profit margin eased a -5.36% compared to previous quarter when profit margin was 6.99%. When comparing sales to same quarter last year, Omnicell sales marked a cool gain and rocketed a 10.90%.
|2017-Q2||$181 M||-||$1 M0.5%||-|
|2017-Q3||$187 M||3.26%||$6 M3.3%||644.32%|
|2017-Q4||$200 M||6.98%||$21 M10.7%||242.09%|
|2018-Q1||$183 M||-8.61%||$3 M1.5%||-87.24%|
|2018-Q2||$189 M||3.32%||$7 M3.5%||142.21%|
|2018-Q3||$204 M||8.27%||$14 M6.7%||106.86%|
|2018-Q4||$212 M||3.66%||$15 M7.0%||8.55%|
|2019-Q1||$203 M||-4.36%||$3 M1.6%||-77.80%|
Omnicell ownershipWhen you are planning to invest in shares of a company, it's worth to overview its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Omnicell, 2.06% of all outstanding shares are owned by its staff.
Bearish positions for OMCL stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Omnicell:
|Market cap||$3.1 B||$17.6 B||$14.3 B||$21.8 B||$265.7 M|
|Total shares||41.7 M||208.3 M||298.1 M||318.4 M||33.7 M|
|Float shares||40.9 M||151.0 M||296.9 M||307.1 M||31.2 M|
|- Institutional holdings (%)||96.5%||68.0%||92.4%||82.8%||124.2%|
|- Insider holdings (%)||2.1%||27.1%||0.3%||4.4%||3.5%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, September 20th, 2019|
|Day range||$73.02 - $74.55|
|Average true range||$2.44|
|50d mov avg||$71.61|
|100d mov avg||$77.28|
|200d mov avg||$75.57|
Omnicell performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. In the following table, we compare Omnicell performance to , Cardinal Health, Cerner, Invacare, McKesson and Premier: